Navigation Links
New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder

Nausea generally was transient, usually resolving within the first week. Nine patients (9 percent) had hypertension during the trial. Six patients reported a serious adverse event, none of which was considered related to desvenlafaxine succinate. Adverse events were noted as the cause of discontinuation from the study in about one-third of patients -- with the majority of discontinuations occurring in the first week. Study findings also showed that HAM-D17 mean total scores steadily decreased from baseline at Day 7 through Day 60 and continued to decrease through the end of the study.

Poster NR363: Ahmed S, et al. Switch from Venlafaxine to Desvenlafaxine Succinate Is Well-Tolerated in Patients with Major Depressive Disorder

In this study, patients taking venlafaxine ER were able to transition to desvenlafaxine succinate with a lower incidence of nausea than patients who switched from placebo to 200 mg/day of desvenlafaxine succinate. Furthermore, patients who switched from venlafaxine ER to desvenlafaxine succinate and those who remained on desvenlafaxine succinate were less likely to discontinue therapy than patients who switched from placebo to 200 mg/day of desvenlafaxine succinate (without titration).

Before joining the 10-week, open-label study, 517 patients completed one of two eight-week, double-blind, placebo-controlled, flexible-dose studies of desvenlafaxine succinate and venlafaxine ER. Patients who received either placebo (n=186) or venlafaxine ER (n=183) during the double-blind study began the open-label phase at 200 mg/day of desvenlafaxine succinate, while patients who took desvenlafaxine succinate (n=148) during the double-blind study remained on the same dose at the beginning of the open-label study. Based on clinical response, each patient's dose of desvenlafaxine succinate could be adjusted during the open-label study.

Study findings show that overall treatment-emergent adverse events reported during the 10-week study
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:1/22/2015)...  Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... to treat voiding dysfunctions, today reported financial results for ... Global revenue for the Company,s Urgent ®  PC ... quarterly revenue record, as compared to $3.9 million in ...
(Date:1/22/2015)... WOODBRIDGE, ON , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics ... company with a focus on Omega-3 therapies for cardiovascular disease ... summary of the Company,s accomplishments in 2014 and its outlook ... Dear Fellow Shareholders, We would like ...
(Date:1/22/2015)... 2015  Bio-Techne Corporation (NASDAQ: TECH ) announced ... of the new Simple Plex platform through its Proteins ... the re-branding of the previously acquired CyPlex instrument platform ... a transformative immunoassay technology which integrates an innovatively designed ...
Breaking Medicine Technology:Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3
... /PRNewswire-Asia/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: ... patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded ... the earnings conference call for the third quarter of ... be held at 9:00 a.m. ET on Tuesday, May ...
... 2012 First Quarter Total Revenue $856 million, including $66 million ... forma organic growth for the combined company, adjusting for the impact ... 2012 First Quarter GAAP EPS Loss of $0.04; Cash EPS ... was $0.99 , 2012 First Quarter GAAP Cash ...
Cached Medicine Technology:TPI to Host Third Quarter of Fiscal Year 2012 Earnings Conference Call on Tuesday, May 15, 2012 at 9:00 a.m. ET 2Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 2Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 3Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 4Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 5Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 6Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 7Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 8Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 9Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 10Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 11Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 12Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 13Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 14Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 15Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 16
(Date:1/22/2015)... January 22, 2015 Deer Path of Huntley ... a Valentine’s Day Happy Hour from 3 p.m. to 4 p.m. ... Regency Parkway in Huntley, Illinois, serves adults with physical disabilities between ... will include Valentine's Day treats, games and sweetheart-themed karaoke. , For ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The City of West ... 10 a.m., to commemorate the 42nd anniversary of the Supreme Court ... , “It’s been 42 years since the Roe vs. Wade decision ... still as present as ever,” said City of West Hollywood Councilmember ...
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 AngelWeddingDress, the ... of 2015 maternity wedding dresses. View website ... are looking for maternity wedding dresses online for a ... gowns with high quality for them. Its maternity wedding ...
(Date:1/22/2015)... 22, 2015 Thousand of GranuFlo lawsuits ... recalled its GranuFlo and NaturaLyte dialysis concentrates continue to ... U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP ... Court has remanded a case filed by the state ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... as Titan of Business & ... ... Washington DC,business community leaders achieved extraordinary fundraising success on,Saturday ... guests,to the Washington Convention Center for one of DC,s largest ...
... Park Ridge, Ill. (April 3, 2008) Choline, an essential nutrient ... 24 percent reduced risk of breast cancer, according to a ... of Health (NIH), to be published in The FASEB Journals ... body of evidence that links egg consumption to a decreased ...
... like dementia are on the rise. And, thanks to ... will be at the forefront of research dealing with ... research teams have won National Health and Medical Research ... in hospitals, transitions to residential care and ascertaining the ...
... 3, 2008 TeamStaff, Inc.,(Nasdaq: TSTF ) ... today announced that it entered into a three ... agreement with Sovereign,Business Capital ("SBC", formerly Business Alliance ... loan credit facility, SBC takes,assignment of TeamStaff,s prior ...
... Edwards,Lifesciences Corporation (NYSE: EW ), a global ... disease, today announced that,its chairman and chief executive ... trading plan under Rule 10b5-1 of the Securities ... similar plan that expired last,month., The new ...
... degree made attempt, but economic status also plays role ... that promote quitting smoking are more likely to have ... dangers of secondhand smoke have a similar effect on ... Wisconsin study. , In 2002 and 2003, researchers ...
Cached Medicine News:Health News:DC's Business Leaders Raise $3.3 Million at Annual Leukemia Ball Featuring Jay Leno 2Health News:DC's Business Leaders Raise $3.3 Million at Annual Leukemia Ball Featuring Jay Leno 3Health News:DC's Business Leaders Raise $3.3 Million at Annual Leukemia Ball Featuring Jay Leno 4Health News:Essential nutrient found in eggs reduces risk of breast cancer by 24 percent 2Health News:Essential nutrient found in eggs reduces risk of breast cancer by 24 percent 3Health News:Better care for dementia patients through new funding 2Health News:TeamStaff Announces Amended Revolving Credit Facility with Sovereign Business Capital 2Health News:TeamStaff Announces Amended Revolving Credit Facility with Sovereign Business Capital 3Health News:Edwards Lifesciences' Chairman and CEO Adopts New 10b5-1 Stock Trading Plan to Replace Recently Expired Plan 2Health News:Better-Educated Smokers More Likely to Quit After Seeing Ads 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: